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The authors would like to correct the following errors: on page 64; paragraph 1, "RTG doses for treatment of early-stage PD monotherapy range from 2 mg/24 hours to 6 mg/24 hours, with recommended titration of 2 mg/24 hours weekly.^5^ For adjunct therapy in advanced-stage PD, RTG may be started at 4 mg/24 hour period and titrated up weekly by an additional 2 mg/24 hour period, with a maximum recommended dose of 16 mg/24 hours.^7^" should be "RTG doses for treatment of early-stage PD monotherapy range from 2 mg/24 hours to 8 mg/24 hours (2--6 mg/24 hours in the US), with recommended titration of 2 mg/24 hours weekly.^5^ For adjunct therapy in advanced-stage PD, RTG may be started at 4 mg/24 hour period and titrated up weekly by an additional 2 mg/24 hour period, with a maximum recommended dose of 16 mg/24 hours (4--8 mg/24 hours in the US).^5^"

On page 64; paragraph 5, "The mean RTG dose was 8 mg/24 hours, while the mean ropinirole dose was 14.1 mg/day." should have been "The majority of patients (92%) received RTG maintenance dose of 8 mg/24 h, while the median ropinirole dose was 14.1 mg/day."

On page 64; paragraph 6, "Three hundred and forty-one patients were randomized to receive RTG 8 mg/24 hours, 12 mg/24 hours, or placebo for 28 weeks." should have been "Three hundred and forty-one patients were randomized to receive RTG up to 8 mg/24 hours, up to 12 mg/24 hours, or placebo for 28 weeks."

On page 65; [Table 1](#t1-dnnd-6-013){ref-type="table"}, data in the Doses column and the Notes section have been updated.

On page 66; paragraph 2, "In an open-label study, advanced-PD patients were treated with levodopa, pramipexole (\<1.5 mg/day), or ropinirole (\<6.0 mg/day), and RTG (\<8 mg/24 hours) for an 8-week treatment period.^7^" should have been "In an open-label study, advanced-PD patients were treated with levodopa, pramipexole (≤1.5 mg/day), or ropinirole (≤6.0 mg/day), and RTG (≤8 mg/24 hours) for an 8-week treatment period.^7"^

On page 68; [Table 3](#t2-dnnd-6-013){ref-type="table"}, data in the Study, doses column for the Stiasny-Kolster study and the Notes section have been updated.

On page 69; [Table 4](#t3-dnnd-6-013){ref-type="table"}, the data for the Stiasny--Kolster study and the Notes section have been updated.

###### 

Efficacy of RTG in early and advanced PD

                                                             Dose (mg/24 hour)                                          n                     Change from baseline ± SD (*P*-value)            
  ---------------------------------------------------------- ---------------------------------------------------------- --------------------- ------------------------------------------------ ------------------------------------------------
  Early PD                                                                                                                                                                                     
   Güldenpfennig et al^20^                                   8 mg/24 hour[a](#tfn1-dnnd-6-013){ref-type="table-fn"}     25                    −2.84±3.45 (0.0004)                              −4.88±5.56 (0.0002)
  \<8 mg/24 hour[a](#tfn1-dnnd-6-013){ref-type="table-fn"}   4                                                          −2.25±2.36 (0.1622)   −3.00±3.56 (0.1671)                              
  Plo                                                        0                                                          --                    --                                               
   Jankovic et al^21^                                        5.7 mg/24 hour[b](#tfn2-dnnd-6-013){ref-type="table-fn"}   177                   −0.39 ±0.26 (0.002)                              −3.58±0.54 (0.001)
  Plo                                                        96                                                         0.92±0.35 (0.002)     0.38±0.73 (0.001)                                
   Parkinson Study Group^22^                                 2 mg/24 hour[a](#tfn1-dnnd-6-013){ref-type="table-fn"}     49                    −0.04 (0.94)                                     −0.90 (0.44)
  4 mg/24 hour[a](#tfn1-dnnd-6-013){ref-type="table-fn"}     47                                                         −0.84 (0.11)          −1.88 (0.11)                                     
  6 mg/24 hour[a](#tfn1-dnnd-6-013){ref-type="table-fn"}     48                                                         −0.92 (0.08)          −3.91 (0.001)                                    
  8 mg/24 hour[a](#tfn1-dnnd-6-013){ref-type="table-fn"}     51                                                         −1.56 (0.003)         −3.82 (0.001)                                    
  Plo                                                        47                                                         --                    --                                               
   Watts et al^23^                                           5.7 mg[b](#tfn2-dnnd-6-013){ref-type="table-fn"}           180                   −0.30±3.54                                       −3.50±7.26
  Plo                                                        96                                                         --                    --                                               
   Giladi et al^2^                                           8 mg[c](#tfn3-dnnd-6-013){ref-type="table-fn"}             215                   −2.1[d](#tfn4-dnnd-6-013){ref-type="table-fn"}   −5.2[d](#tfn4-dnnd-6-013){ref-type="table-fn"}
  Plo                                                        118                                                        −0.1                  −2.1                                             
   Trenkwalder et al^25^                                     2--16 mg                                                   178                   −2.6±3.6                                         −7.0 (0.002)
  Plo                                                        89                                                         −1.3±3.4              −3.9                                             
  Advanced PD                                                                                                                                                                                  
   LeWitt et al^26^                                          ≤8 mg/24 h                                                 113                   −3.1 (0.004)                                     −6.8 (0.0185)
  ≤12 mg/24 h                                                109                                                        −3.2 (0.0023)         −8.7 (0.0006)                                    
  Plo                                                        119                                                        −0.5                  −3.4                                             
   Poewe et al^27^                                           4--16 mg/24 hour                                           201                   −4.2±4.5 (\<0.0001)                              −8.7±8.0 (\<0.0001)
  Plo                                                        100                                                        −2.0±4.3 (\<0.0001)   −4.3±9.3 (\<0.0001)                              

**Notes:**

RTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information^5^), ie, 4.5 mg is equivalent to 2 mg/24 h, 9 mg to 4 mg/24 h, 13.5 mg to 6 mg/24 h, and 18 mg to 8 mg/24 h;

The mean (SD) dose was 5.7 (0.84) mg/24 h; 6 mg dose for majority of participants;

Ninety-two percent of those in the RTG group were treated with this dose in the maintenance phase and 8% had lower doses; there was no SD reported for UPDRS II or III separately; however, the combined UPDRS part III + part II scores were significantly more improved compared to placebo at the end of the maintenance phase (*P*\<0.0001);

there was no SD reported for UPDRS II or III separately, however the combined UPDRS part III + part II scores were significantly more improved compared to placebo at the end of the maintenance phase (*P*\<0.0001).

**Abbreviations:** RTG, rotigotine; PD, Parkinson's disease; UPDRS II, Unified Parkinson's Disease Rating Scale part II (activities of daily living); UPDRS III, Unified Parkinson's. Disease Rating Scale part III (motor examination); Plo, placebo.

###### 

Efficacy of RTG in RLS -- change from baseline ± SD (*P*-value)

  Study, dose (mg/24 hour)                                    n     IRLS total score ± SD (*P*-value)   CGI-1 score ± SD (*P*-value)   PSQI total score ± SD (*P*-value)
  ----------------------------------------------------------- ----- ----------------------------------- ------------------------------ -----------------------------------
  Inoue et al^40^                                                                                                                      
   2 mg                                                       95    −14.3±8.9 (0.030)                   --                             −3.1±3.2 (0.188)
   3 mg                                                       94    −14.6±9.0 (0.016)                   --                             −3.2±3.3 (0.112)
   Plo                                                        95    −11.6±8.2                           --                             −2.5±2.4
  Oertel et al^24^                                                                                                                     
   2 mg[a](#tfn6-dnnd-6-013){ref-type="table-fn"}             41    −16.5±9.3                           −2.7±1.4                       --
   Plo                                                        20    −9.9±9.9                            −1.7±1.5                       --
  Hening et al^10^                                                                                                                     
   0.5 mg                                                     98    −10.9±8.9 (0.0682)                  4.7±0.8 (0.0603)               --
   1 mg                                                       99    −11.1±9.3 (0.0535)                  4.6±0.7 (0.0857)               --
   2 mg                                                       95    −13.4±9.2 (0.0002)                  4.7±0.8 (0.0007)               --
   3 mg                                                       103   −14.3±9.4 (\<0.0001)                4.7±0.8 (\<0.0001)             --
   Plo                                                        99    −9.0±7.7                            4.7±0.6                        --
  Trenkwalder et al^8^                                                                                                                 
   1 mg                                                       148   −14.0±0.8 (\<0.0001)                −2.13±0.12 (\<0.0001)          --
   2 mg                                                       96    −16.4±1.0 (\<0.0001)                −2.41±0.14 (\<0.0001)          --
   3 mg                                                       92    −16.8±1.1 (\<0.0001)                −2.55±0.17 (\<0.0001)          --
   Plo                                                        111   −8.7±0.9                            −1.37±0.15                     --
  Oertel et al^9^                                                                                                                      
   0.5 mg                                                     50    −10.5±9.2 (0.2338)                  −1.6±1.4                       --
   1 mg                                                       64    −15.3±10.0 (0.0004)                 −2.2±1.5 (\<0.05)              --
   2 mg                                                       49    −15.7±9.5 (0.0003)                  −2.4±1.3 (\<0.05)              --
   3 mg                                                       64    −17.3±10.5 (\<0.0001)               −2.7±1.6 (\<0.05)              --
   4 mg                                                       53    −14.9±10.3 (0.0013)                 −2.3±1.5 (\<0.05)              --
   Plo                                                        53    −9.3±9.6                            −1.5±1.4                       --
  Stiasny-Kolster^41^                                                                                                                  
   0.5 mg/24 hour[b](#tfn7-dnnd-6-013){ref-type="table-fn"}   19    −10.5±2.0                           --                             --
   1 mg/24 hour[b](#tfn7-dnnd-6-013){ref-type="table-fn"}     13    −12.3±2.3                           --                             --
   2 mg/24 hour[b](#tfn7-dnnd-6-013){ref-type="table-fn"}     17    −15.7±1.9                           --                             --
   Plo                                                        14    −8.0±2.2                            --                             --

**Notes:**

A mean dose of RTG in the treatment group was reported as 2.1 mg/24 hours;

RTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information^5^), ie, 1.125 mg is equivalent to 0.5 mg/24 h, 2.25 mg to 1 mg/24 h, and 4.5 mg to 2 mg/24 h.

**Abbreviations:** RTG, rotigotine; RLS, restless legs syndrome; SD, standard deviation; IRLS, International Restless Legs Syndrome Study Group severity rating scale; CGI-1, Clinical Global Impressions item-1; PSQI, Pittsburgh Sleep Quality Index; Plo, placebo.

###### 

Side effects present in participants (%) during randomized, double--blinded, placebo--controlled trials

  Side effect                 Dose (mg/24 hour)   Inoue et al^40^   Hening et al^10c^   Trenkwalder et al^8^   Oertel et al^9^   Oertel et al^24^,[a](#tfn9-dnnd-6-013){ref-type="table-fn"}   Stiasny--Kolster^41^,[b](#tfn10-dnnd-6-013){ref-type="table-fn"}                                    
  --------------------------- ------------------- ----------------- ------------------- ---------------------- ----------------- ------------------------------------------------------------- ------------------------------------------------------------------ ------ ------ ---- ------ ------ ------
  Application site reaction   0.5 mg              --                7.4                 22.2                   5.0               --                                                            --                                                                 9.8    1.8    --   4.8    17.6   28.6
  1 mg                        --                  --                17                  --                     35.0              2.0                                                           15.6                                                               --     --     --   38.5   --     
  2 mg                        42.1                --                34.3                --                     41.0              --                                                            16.3                                                               --     17.4   --   26.3   --     
  3 mg                        50.0                --                34                  --                     52.0              --                                                            20                                                                 --     --     --   --     --     
  4 mg                        --                  --                --                  --                     --                --                                                            25                                                                 --     --     --   --     --     
  Headache                    0.5 mg              --                0                   14.1                   8.0               --                                                            --                                                                 11.8   7.3    --   14.3   11.8   7.1
  1 mg                        --                  --                12                  --                     10.0              7.0                                                           7.8                                                                --     --     --   38.5   --     
  2 mg                        5.3                 --                10.1                --                     13.0              --                                                            2                                                                  --     17.4   --   21.1   --     
  3 mg                        2.1                 --                10.4                --                     16.0              --                                                            4.6                                                                --     --     --   --     --     
  4 mg                        --                  --                --                  --                     --                --                                                            12.5                                                               --     --     --   --     --     
  Nausea                      0.5 mg              --                9.5                 13.1                   10.0              --                                                            --                                                                 5.9    9.1    --   4.8    0.0    14.3
  1 mg                        --                  --                20                  --                     9.0               --                                                            9.4                                                                --     --     --   7.7    --     
  2 mg                        33.7                --                18.2                --                     21.0              --                                                            6.1                                                                --     21.7   --   5.3    --     
  3 mg                        43.6                --                20.8                --                     18.0              --                                                            24.6                                                               --     --     --   --     --     
  4 mg                        --                  --                --                  --                     --                --                                                            23.2                                                               --     --     --   --     --     
  Fatigue                     0.5 mg              --                --                  10.1                   4.0               --                                                            --                                                                 3.9    9.1    --   9.5    0.0    0.0
  1 mg                        --                  --                3                   --                     7.0               9.0                                                           4.7                                                                --     --     --   0.0    --     
  2 mg                        --                  --                7.1                 --                     15.0              --                                                            6.1                                                                --     8.7    --   10.5   --     
  3 mg                        --                  --                6.6                 --                     11.0              --                                                            10.8                                                               --     --     --   --     --     
  4 mg                        --                  --                --                  --                     --                --                                                            7.1                                                                --     --     --   --     --     
  Pruritus                    0.5 mg              --                --                  9.1                    2.0               --                                                            --                                                                 5.9    1.8    --   --     5.9    7.1
  1 mg                        --                  --                2                   --                     --                --                                                            3.1                                                                --     --     --   15.4   --     
  2 mg                        --                  --                3                   --                     --                --                                                            0                                                                  --     --     --   0.0    --     
  3 mg                        --                  --                7.5                 --                     --                --                                                            10.8                                                               --     --     --   --     --     
  4 mg                        --                  --                --                  --                     --                --                                                            3.6                                                                --     --     --   --     --     
  Hyperhidrosis               0.5 mg              --                --                  --                     --                --                                                            --                                                                 --     --     --   --     --     0.0
  1 mg                        --                  --                --                  --                     5.0               3.0                                                           --                                                                 --     --     --   0.0    --     
  2 mg                        --                  --                --                  --                     6.0               --                                                            --                                                                 --     --     --   0.0    --     
  3 mg                        --                  --                --                  --                     4.0               --                                                            --                                                                 --     --     --   10.5   --     
  4 mg                        --                  --                --                  --                     --                --                                                            --                                                                 --     --     --   --     --     
  Somnolence                  0.5 mg              --                2.1                 8.1                    6.0               --                                                            --                                                                 --     --     --   9.5    --     --
  1 mg                        --                  --                10.0                --                     --                --                                                            --                                                                 --     --     --   --     --     
  2 mg                        10.5                --                13.1                --                     --                --                                                            --                                                                 --     10.9   --   --     --     
  3 mg                        --                  --                15.1                --                     --                --                                                            --                                                                 --     --     --   --     --     
  4 mg                        --                  --                --                  --                     --                --                                                            --                                                                 --     --     --   --     --     

**Notes:**

The study did not report the association of adverse events (AE) in relation to the dose of RTG. A mean dose of RTG in the treatment group was reported as 2.1 mg/24 hours;

RTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information^5^), ie, 1.125 mg is equivalent to 0.5 mg/24 h, 2.25 mg to 1 mg/24 h, and 4.5 mg to 2 mg/24 h.

**Abbreviations:** RTG, rotigotine; Plo, placebo.
